comprehensive -WSS

comprehensive

author：leisure time 2025-09-29 22:51:08 - browse：24

Senate Finance Committee Chair Ron Wyden (D-Ore.) Leah Millis/Pool via AP

WASHINGTON — Senators on the Finance Committee on Wednesday nearly unanimously passed a bill to clamp down on drug middlemen, but kicked the can down the road on some of the more challenging policies.

The bill would offer some more transparency into the business practices of pharmacy benefit managers, ensure PBMs aren’t skimming off of the money they send to insurers, prohibit them from overcharging insurers, and ensure certain fees in the Medicare program aren’t tied to a drug’s price.

“It’s pretty hard to get 26 votes around here,” Finance Chair Ron Wyden (D-Ore.) said after the vote. “So we’re thrilled.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： David Sabatini, ex

WSS

Ransomware attacks on hospitals: Study outlines patient impact

Weight loss drug costs may need more research, senator suggests

What to know about the judge who will handle the Trump case

Schizophrenia gene found to be linked to cells' energy dysfunction

Judge sides with young activists in first

Megan Rapinoe shares emotional post following US Women's World Cup exit

hotspot

comprehensive

Wikipedia

Medical records are filled with copy

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

As demand for Covid shots wanes, Moderna seeks its next success

Anthos stroke drug appears safer than common blood thinner

Hepatitis C has a cure — but many Americans still lack access to it

Weight loss drug costs may need more research, senator suggests

New air purifier tech could be key to improving indoor air quality

Astellas still sees hope in its gene therapy after four deaths

ChatGPT in medicine: STAT answers readers' burning questions

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

focus

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Wegovy, Zepbound and weight loss drugs that preserve muscle

Weight loss drug costs may need more research, senator suggests

Illinois Supreme Court finds assault weapons ban constitutional

hotspot

entertainment

explore

Wikipedia